Close Button Icon
Doptelet (avatrombopag) Tablets Logo

You are about to leave DOPTELETHCP.com and go to an external page.

Please note that Sobi is not responsible for the content of the website you are about to visit.

CONTINUE

Go back

This information is intended for healthcare professionals in the United States.

Are you a healthcare professional?

Yes

No
Close Button Icon

Discover the Doptelet Copay Program

Eligible commercially insured patients may qualify for the Doptelet Connect program

What's the program?

  • Eligible patients may pay as little as $0 for each Doptelet prescription
  • Annual maximum benefit up to $15,000

Eligible patients must:

  • Have commercial insurance that covers Doptelet
  • Not be enrolled in any state or federal healthcare program such as Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD), or TRICARE
  • Be 18 years of age or older
  • Be a resident in the United States or a US Territory

How to enroll:

  • Approved pharmacies, healthcare professionals, and Doptelet Connect can enroll patients
  • Patients can enroll themselves as well as their caregivers
  • Please call 1-833-368-2663 Monday–Friday 8 am–8 pm ET for more information

Terms and Conditions

  • Patients pay as little as $0 per prescription. Copay Program has an annual calendar cap of $15,000
  • The Copay Saving Program is void where prohibited by law, taxes, or restricted
  • This offer is non-transferable, no substitutions are permissible, and this offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
  • Sobi, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice
  • The Patient Copay Program for Doptelet is not insurance and is not intended to substitute for insurance
  • Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Copay Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount of assistance received from the Copay Program
  • Certain information pertaining to your use of the Copay Program will be shared with Sobi, Inc., the sponsor of the Copay Program. The information disclosed will include the date the prescription is filled, the number of pills or product dispensed by the pharmacists, and the amount of your copay that will be paid for by using this Copay Program. For more information, please see the Sobi Privacy Policy at https://sobi-northamerica.com/privacy-policy
  • Acceptance in this Program is not conditioned on any past, present, or future purchase, including additional doses
  • Enrollment for the Copay Program is valid through the calendar year
  • Sobi reserves the right to change program terms at any time
Close Button Icon
  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
  • Request a Rep
  • For US healthcare professionals only

  • Important Safety Information
  • Prescribing Information
  • Patient Information Leaflet
  • For Patients
Doptelet (avatrombopag) Tablets Logo

For US healthcare professionals only

  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
  • Request a Rep

CONSISTENT EFFICACY

In 2 pivotal studies that included procedures ranging from low to high bleeding risk.1

ADAPT‐1 and ADAPT‐2 were 2 identically designed, multicenter, randomized, double‐blind, placebo‐controlled studies (N=435)1,2

Doptelet Dosing Titration Chart for CLD

  • Biliary interventions
  • Bronchoscopy +/- biopsy
  • Chemoembolization for HCC
  • Colonoscopy +/- polypectomy/biopsy
  • Dental procedures
  • Ethanol ablation
  • Laparoscopic interventions
  • Liver biopsy
  • Nephrostomy tube placement
  • Paracentesis
  • Radiofrequency ablation
  • Renal biopsy
  • Thoracentesis
  • Transjugular intrahepatic portosystemic shunt
  • Upper GI endoscopy +/- biopsy
  • Upper GI endoscopy +/- sclerotherapy
  • Upper GI endoscopy +/- variceal banding
  • Vascular catheterization

In the ADAPT studies, the percentage of patients who underwent procedures with low, moderate, or high risk was as follows: low 60.8%; moderate 17.2%; and high 22.1%.1

Procedure Day High Baseline And Low Baseline Efficacy Graph

Primary Endpoint: Patients not requiring a platelet transfusion or any rescue procedure for bleeding up to 7 days following a scheduled procedure

From randomization of Doptelet 40 mg or Doptelet 60 mg once daily for 5 days up to 7 days after a procedure, compared to placebo (P<0.0001; N=435).1,2

88%

of high-baseline patients taking Doptelet achieved the primary endpoint (N=117)1

66%

of low-baseline patients taking Doptelet achieved the primary endpoint (N=90)1

Mean platelet counts nearly doubled with Doptelet1

With Doptelet, platelet counts significantly increased by procedure day1,2

Up to  +45,000  in high-baseline patients and 

+32,000  in low-baseline patients1

Change In Platelet Efficacy Graph

97% of patients whose platelet counts were measured on procedure day had an increase with Doptelet.1,3†

270/277 patients treated with Doptelet in ADAPT-1 and ADAPT-2 had increased platelet counts by procedure day.

Important Safety Information

Thrombotic/Thromboembolic Complications. Doptelet is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Portal vein thrombosis has been reported in patients with chronic liver disease treated with TPO receptor agonists.

Doptelet should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts.

Procedure Day High Baseline And Low Baseline Efficacy Graph

93%

of high-baseline patients reached the
50,000 platelets/μL target (N=58)1,2

69%

of low-baseline patients reached the
50,000 platelets/μL target (N=90)1,2

Explore the safety profile of Doptelet

DOPTELET SAFETY PROFILE
Doptelet Platelet Character Coach Smiling

References:

  1. 1. DOPTELET [package insert]. Durham, NC: AkaRx, Inc.
  2. 2. Terrault N, Chen Y-C, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):705-718.
  3. 3. Data on file. 2018: Sobi, Inc.
INDICATION & IMPORTANT
SAFETY INFORMATION

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions

The most common serious adverse reaction reported in DOPTELET-treated patients compared to placebo was hyponatremia (0.7% v. 0%).

Adverse Reactions

The most common adverse reactions (≥3%) in patients with chronic liver disease were: pyrexia, abdominal pain, nausea, headache, fatigue, and peripheral edema.

Postmarketing Experience

Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

For WAC pricing, visit doptelethcp.com/wac-pricing.

Sobi Rare Strength Logo
Terms of Use
Privacy Policy
Contact Us
Unsubscribe

Doptelet is a registered trademark of AkaRx, Inc.
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
Doptelet Connect is a trademark of AkaRx, Inc.
© 2022 Sobi, Inc. – All rights reserved

PP-14800   04/22

INDICATION & IMPORTANT
SAFETY INFORMATION
Open ISI Button
Close ISI Button

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Scroll To Top Button

This website uses cookies. By continuing to use this website, you consent to our use of these cookies.

Read more about our use of cookies